Grants and Contributions:
Title:
Development of Hepatitis C Omnibus Portal (hepMD)
Agreement Number:
935347
Agreement Value:
$160,000.00
Agreement Date:
Oct 1, 2019 - Jan 31, 2021
Description:
The hepMD platform will eliminate cumbersome paperwork and allow health care providers to quickly get their patients on to one of the new oral HCV therapies - Vosevi (Gilead Sciences Canada), Zepatier (Merck Canada), Maviret (Abbvie Canada). The portal will bring blockchain to prescription management as a novel way of dealing with the very problematic issue related to digitally prescribing pharmaceuticals in Canada.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M6B 1W3
Reference Number:
172-2019-2020-Q3-935347
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
859789620
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Amendment Date
Jul 6, 2020
Recipient's Legal Name:
MESHMD INC.
Federal Riding Name:
Eglinton--Lawrence
Federal Riding Number:
35024
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54151
Amendments: